fasudil has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burthem, J | 1 |
| Rees-Unwin, K | 1 |
| Mottram, R | 1 |
| Adams, J | 1 |
| Lucas, GS | 1 |
| Spooncer, E | 1 |
| Whetton, AD | 1 |
1 other study available for fasudil and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Antigens, CD34; Benzamides; Cell Proliferatio | 2007 |